CLASP II TR 试验:Pascal Precision 设备在重度三尖瓣反流治疗中取得软性胜利
Pascal Tricuspid TEER Handed Soft Victory in 'Hamstrung' CLASP II TR Trial
CLASP II TR 试验显示,Pascal Precision 设备在重度三尖瓣反流患者中改善了健康状况,尽管主要终点未达预期。该试验基于 6 个月的健康状况改善结果,最终获得了 FDA 批准用于三尖瓣修复。
CLASP II TR 试验显示 Pascal Precision 设备在治疗重度三尖瓣反流方面有效,尽管结果未达预期。
— Pascal Precision device was recently approved by the FDA
by Nicole Lou, Senior Staff Writer, MedPage Today
November 4, 2026 • 4 min read
The Pascal Precision transcatheter edge-to-edge repair (TEER) system eked out a win in symptomatic severe tricuspid regurgitation (TR) in its pivotal randomized trial.
In CLASP II TR, there was significant clinical improvement among patients randomized to tricuspid valve TEER plus optimal medical therapy, as opposed to medical therapy alone, in a hierarchical analysis counting all-cause death, right ventricular assist device implantation or heart transplant, tricuspid valve intervention, number of heart failure (HF) hospitalizations, and overall health status.
This primary endpoint produced a win ratio of 1.98 favoring the Pascal Precision (95% CI 1.47-2.67), reported Charles Davidson, MD, of Northwestern Memorial Hospital in Chicago, at the Transcatheter Cardiovascular Therapeutics (TCT) annual conference hosted by the Cardiovascular Research Foundation.
The TEER benefit was driven by 6-month health status improvement alone: Kansas City Cardiomyopathy Questionnaire (KCCQ) scores were on average over 10 points higher in the device group compared with controls, according to co-trialist Suzanne Arnold, MD, MHA, of Saint Luke's Mid America Heart Institute in Kansas City, Missouri, speaking alongside Davidson.
"The CLASP II TR trial demonstrates safety and efficacy of the Pascal system to improve health status in symptomatic patients with [severe or greater] TR," the study authors concluded.
The efficacy results were not what the authors had originally hoped for, however, as CLASP II TR was initially designed for a 24-month primary endpoint -- only later revised to 6 months due to control group attrition to commercial therapy following FDA approval of the Evoque tricuspid valve replacement system and the TriClip G4 TEER device in 2024.
Still, it was on the basis of this study that the Pascal Precision recently got FDA approval for tricuspid valve repair. Initially, the device had entered the market for mitral TEER in 2022.
Co-investigator and TCT panelist Rebecca Hahn, MD, of NewYork-Presbyterian/Columbia University Irving Medical Center in New York City, maintained that despite the "hamstrung" analyses in CLASP II TR, "it does in the end add to the literature supporting the treatment of these patients with [tricuspid] TEER."
Indeed, CLASP II TR marks the fourth trial (after TRILUMINATE, Tri.Fr, and TRIC-I-HF) to show superiority of tricuspid valve repair over medical therapy, especially concerning patient-reported outcomes, noted Jörg Hausleiter, MD, of Klinikum Der Universitat Munchen in Germany, the study discussant at TCT.
In fact, Hausleiter's TRIC-I-HF study had the distinction of being the landmark study showing that, among the selected population of sicker people with severe TR at high risk for future HF events, transcatheter tricuspid intervention reduced all-cause death and HF hospitalization while improving quality of life.
Davidson and Arnold reported that their trial was also able to give tricuspid TEER the edge for proportion of patients alive with ≥20-point improvements in the KCCQ overall score at 6 months (38.8% vs 12.3%, P<0.001), as well as the proportion alive with more modest ≥10-point improvements in KCCQ (57.1% vs 25.4%, P<0.001). Additionally, those achieving moderate or better TR at 1 year came out to 80% with the device versus 30% with only medical therapy.
For the TEER recipients, the composite safety event rate reached 6.9% at 30 days and 20.1% at 1 year. Among the most frequent events were single leaflet device attachment (3.4% and 4.8%, respectively), severe bleeding (3.1% and 8.5%), and cardiovascular mortality (0.3% and 5.4%).
"I think it's important to help people feel better," said Patrick O'Gara, MD, of Brigham and Women's Hospital in Boston, also a panelist at TCT. "If patients are feeling better, it's a good outcome provided the procedure is safe and is provided by people who are expert in its implementation."
"In some ways, we should be cautious, we need to temper expectations ... There are huge gaps between expectations and the reality of what we're able to achieve," O'Gara told the audience.
The CLASP II TR trial, conducted in the U.S. and Canada, had participants with severe-or-worse TR randomized to Pascal Precision TEER with medical therapy (n=294) or medical therapy alone (n=148).
The cohort averaged about 80 years old, with just under half being women. Nearly 60% had New York Heart Association class III-IV symptoms. STS-PROM (for mitral valve repair) scores were about 7.5%. Approximately one in four people had a HF hospitalization in the past 12 months.
TR etiology was largely secondary (over 75%) and most commonly graded as severe (58%) as opposed to massive or torrential.
The authors reported that 92.5% of the treatment arm got the device implanted successfully. This group was roughly split between those who got one and two devices.
Davidson and Arnold noted that their open-label trial left room for a placebo effect. Participating centers and operators also generally had limited prior experience with the Pascal system, they added.
One important remaining question is when operators should intervene on TR.
During a press conference, Roxana Mehran, MD, of Mount Sinai Hospital in New York City, stressed the importance of the heart team and the fact that in the U.S., tricuspid TEER is still covered with evidence development. The expectation is that TVT registry data will continue to accrue to show who is the right patient at the right time for tricuspid TEER, she suggested.
The TVT registry has the downside of being single-arm, Arnold noted, but she agreed that it will still be helpful for providing long-term data.
来源:MedPage Today · medpagetoday.com